<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321449</url>
  </required_header>
  <id_info>
    <org_study_id>A-38-59010-001</org_study_id>
    <nct_id>NCT02321449</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over</brief_title>
  <acronym>QUALISLEEP</acronym>
  <official_title>Open-label, Post-marketing Observational Study to Evaluate the Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of treatment with Circadin based on sleep improvement as
      assessed by the modified Questionnaire Scoring Subjective Characteristics of Sleep before and
      after the treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in quality of sleep questionnaire</measure>
    <time_frame>Baseline, 3 weeks</time_frame>
    <description>Sleep improvement as assessed by the modified Questionnaire Scoring Subjective Characteristics of Sleep before and after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in attention Questionnaire</measure>
    <time_frame>Baseline, 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in memory Questionnaire</measure>
    <time_frame>Baseline, 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients responding &quot;unsatisfied&quot;, &quot;effective therapy&quot;, &quot;very effective therapy&quot;, respectively, in the patient satisfaction assessment</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Insomnia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult male and female patients aged ≥ 55 years suffering from primary (non-organic)
        insomnia characterized by poor quality of sleep
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged ≥ 55 years suffering from non-organic insomnia according
             to International Classification of Diseases (ICD-10)

          -  Patients with sleep disorders manifested as poor sleep quality associated with
             impaired daytime functioning with or without one or more of the following criteria:
             difficulty falling asleep, frequent night awakenings, early morning awakenings

          -  Patients able to follow the study protocol

          -  Patients who have signed the Informed Consent prior to initiation of any
             observation-related procedures

          -  Patients with a global score of ≤17 inclusively on the modified Questionnaire Scoring
             Subjective Characteristics of Sleep

          -  Patients who have just been identified to receive treatment with Circadin

          -  Patients without previous treatment with Circadin

        Exclusion Criteria:

          -  Hypersensitivity to any components of Circadin

          -  Congenital galactose intolerance, glucose-galactose malabsorption, Lapp lactase
             deficiency

          -  Pregnancy and lactation

          -  Alcohol or drug addiction

          -  Severe somatic and neurological conditions, exacerbations thereof, including
             autoimmune diseases or renal/hepatic insufficiency

          -  Intake of psychoactive medicines within the last 30 days before observational study
             entry

          -  Presence of clinically significant anxiety and depression as assessed by the Hospital
             Anxiety and Depression Scale

          -  Presence of pain that might be the cause for insomnia. Subjects suffering from
             breathing related sleep disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Poznyakova, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State research center of preventive medicine</name>
      <address>
        <city>Moscow</city>
        <zip>101000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research and Education Center of Moscow State University named after M.V. Lomonosov</name>
      <address>
        <city>Moscow</city>
        <zip>119192</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <last_update_submitted>June 29, 2015</last_update_submitted>
  <last_update_submitted_qc>June 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

